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Introduction
Diabetes is an epidemic estimated by the International 
Diabetes Federation to affect more than 415 million peo-
ple worldwide.1 Diabetes mellitus, a disease caused by 
either reduced insulin production due to autoimmune 
eradication of pancreatic β-cells (type 1) or peripheral 
insulin resistance (type 2), eventually results in severe 
hyperglycemia, organ failure, and increased morbidity, 
and, possibly, mortality.2 Failure in glucose homeostasis 
can result in various auxiliary complications such as car-
diovascular disease, and according to the Centers for 
Disease Control and Prevention, it is the main cause of 
kidney failure, blindness, and amputations.3,4 The current 
standard of care for type 1 diabetes patients involves 
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daily monitoring of blood glucose levels and the continu-
ous injection of insulin,5 and for patients with type 2 dia-
betes, oral or injected therapeutics. Both treatments have 
their respective side effects including ketosis and hypogly-
cemic coma. It is widely accepted that therapies aimed at 
regeneration or replacement of damaged insulin-producing 
β-cells could be a more permanent cure for treating diabe-
tes. Pancreas and islet transplants have shown success at 
re-establishing glucose control and reversing diabetic 
complications, but their routine clinical application is still 
inadequate, primarily due to the limited supply of cadav-
eric organs and loss of graft function over time due to 
immune rejection, lack of neovascularization, and loss of 
physiological architecture. Patients transplanted with 
cadaveric human islets can become insulin independent 
for about 5 years, but limited quantity and quality of 
donor islets make it an unrealistic cure.6,7 The ideal ther-
apy would restore insulin from autologous cell popula-
tions. The discovery of pluripotent stem cells, which 
have the capability of evolving to any cell type, has 
inspired the use of these cells for disease treatment and 
drug screening.8 The ability to produce an unlimited sup-
ply of islet-like insulin-producing aggregates (ILIPAs) 
from stem cells, and the subsequent transplantation to 
easily accessible sites, could result in a permanent cure to 
millions of patients affected by diabetes. In order to sup-
port the long-term survival and function of these trans-
planted cells in the host body and to protect them from 
dispersion, destruction, and immunological attack, sev-
eral micro- and macroencapsulation and delivery strate-
gies have been tried with varied results.9 Polylactic acid 
(PLA) is widely used in many different biomedical appli-
cations due to its biocompatibility, biodegradability, and 
non-toxic degradation products.10 Its long half-life, which 
may not be desirable in other biomedical applications, is 
advantageous in designing long-term implantable devices 
like cell encapsulation systems for diabetes. Furthermore, 
it is possible to modify the surface structure and proper-
ties of PLA through different techniques, allowing better 
biomimetic properties useful to improve its application 
as a cell reservoir scaffold for cells of different origins.11 
In this study, we characterize differentiated ILIPAs from 
adult human bone marrow–derived mesenchymal stem 
cells (BM-MSCs) and compare their genetic signatures to 
pancreatic human islets. We also develop a three- 
dimensional (3D) printed PLA delivery and encapsula-
tion system suitable for possible subcutaneous implanta-
tion of pancreatic cells.
Materials and methods
Human pancreatic islets isolation and 
purification
Human pancreata (n = 5) were obtained from heart-beating 
donors deceased by brain death with informed consent for 
transplant or research use from relatives of the donors. 
Human islets were isolated from cadaver donors using an 
adaptation of the automated method described by Ricordi 
et al.12 See supplementary files for more details.
Islet cell culture
Aliquots from human islet isolations were then cultured in 
Memphis serum-free medium (M-SFM) further supple-
mented with 10 U/mL of heparin and 10 mM of niacin as 
described previously.13 Islet culture medium was changed 
at day 1 post-isolation and thereafter weekly for all islet 
preparations during the culture period. Islet tissue was cul-
tured for 1–3 days prior to experimentation, to allow for 
sterility and viability testing. These islets were used as 
positive controls for BM-MSC-derived ILIPAs.
Isolation, expansion, and differentiation of 
BM-MSCs
Bone marrow samples (n = 5) were recovered from leftover 
tissue in used bone marrow collection bag sets, properly 
consented for research utilization. The age of the bone 
marrow donors ranges from 21–55 years. Isolation, expan-
sion, and differentiation of BM-MSCs were performed 
according to the procedures outlined by Gabr et al.14 See 
supplementary file for more details.
Characterization of isolated mesenchymal stem 
cells by flow cytometry
For flow cytometric analysis, the mesenchymal stem cells 
(MSCs) at passage three were trypsinized, centrifuged at 
300 g for 8 min, and resuspended in phosphate-buffered 
saline (PBS) at a concentration of 1 × 106 cells/mL. A total 
of 100 µL of aliquots were labeled for 30 min with antibod-
ies against CD14, CD45 (fluorescein isothiocyanate 
(FITC)), or CD73; CD34 phycoerythrin (PE; Becton 
Dickinson, USA); or CD106, CD29 PE, or CD44 (FITC; 
Becton Dickinson), washed with 1 mL of stain buffer 
(BD-Pharmingen, USA) and resuspended in 500 µL of 
stain buffer. The labeled cells were analyzed using an 
argon-ion laser with a wavelength of 488 nm (FACS 
Calibur; Becton Dickinson). A total of 10,000 events were 
obtained and analyzed with the DIVA software program 
(Becton Dickinson). Control staining with appropriate 
isotype-matched monoclonal antibodies was included.
Differentiation of the MSCs to ILIPAs
After passage three, MSCs with appropriate CD profiles 
were seeded at a density of 1 × 105 cells/mL in serum-free, 
high-glucose (450 mg/dL) Dulbecco’s Modified Eagle’s 
medium (D-MEM; 25 mmol/L) containing 0.5 mmol/L of 
β-mercaptoethanol (Sigma) and incubated for 2 days. The 
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medium was replaced with serum-free, glucose-rich medium 
containing 1% nonessential amino acids (Sigma), 20 ng/mL 
basic fibroblast growth factor (Sigma), 20 ng/mL epidermal 
growth factor (Sigma), 2% B27 supplement (Gibco BRL, 
Life Technologies, UK), and 2 mmol/L L-glutamine 
(Sigma). The preparations were cultured for 8–10 days. 
Finally, the cells were cultured for an additional 8–10 days 
in serum-free, high-glucose D-MEM containing 10 ng/mL 
betacellulin (Sigma), 10 ng/mL activin-A (Sigma), 2% B27 
supplement, and 10 mmol/L nicotinamide (Sigma).
Immunolabelling
Immunohistochemistry was performed using primary anti-
bodies against insulin (AB6995; Abcam, Cambridge, MA) 
and glucagon (AB92517; Abcam). For nanogold immu-
nostaining, the ILIPAs were fixed in 2% formalin and 
0.5% glutaraldehyde (EM grade from Ted Pella) in PBS 
overnight at 4°C. After washing 3 × 15 min with PBS con-
taining 0.05% Tween 20 (Bio-Rad Laboratories, Hercules, 
CA, USA), ILIPAs were blocked for 6 h in casein blocking 
buffer (Bio-Rad Laboratories) with 0.05% Tween 20 at 
room temperature. Subsequently, samples were incubated 
with mouse monoclonal anti-c-peptide (1H8) antibody 
(Abcam, ab8297) at 1:50 dilution in blocking buffer, over-
night at 4°C. The next day, samples were washed for sev-
eral hours with 0.05% PBS Tween 20 and incubated 
overnight at 4°C with anti-mouse antibody conjugated 
with 1.4 nm gold (Nanoprobes, Yaphank, NY, USA) 
diluted at 1:50 with blocking buffer. The next day, samples 
were washed 3 × 15 min with 0.05% PBS Tween 20, post-
fixed for 20 min in 1% glutaraldehyde in 0.05% PBS 
Tween 20, washed 3 × 15 min in water, silver enhanced, 
and either photographed as a whole mount or processed for 
electron microscopy without the osmium tetraoxide treat-
ment, as described previously. Whole-mount immu-
nostained ILIPAs were contrasted with 0.5% uranyl acetate 
only (without osmium tetraoxide) and embedded in Epon. 
Thin (70–100 nm) sections were examined and photo-
graphed in JEOL 1200 transmission electron microscope.
Microarray analysis
RNA was extracted using the Trizol Hybrid RNA Method, 
RNA quality assessed with the Agilent Bioanalyzer, and 
RNA samples amplified using the Ambion WT Expression 
Kit (Affymetrix). Fragmentation/terminal-labeled RNA 
was hybridized to the Affy 1.1ST human chip and pro-
cessed with the GeneTitan system.
Gene expression by reverse  
transcription–polymerase chain reaction
Total RNA (totRNA) was extracted in accordance with the 
manufacturer’s instructions. Variable amounts of total 
RNA input were reverse transcribed using the iScript 
cDNA Synthesis Kit (Bio-Rad Laboratories), the amount 
defined by the respective samples’ concentration (from 5 
to 1000 ng total RNA input).
TaqMan® (Life Technologies) analysis was performed 
on the Roche LightCycler 480 II Instrument with 
LightCycler® 480 Probes Master mix (Roche). See sup-
plementary Table 2 for the list of TaqMan primers/probes 
analyzed. For more representative normalization, a cDNA 
master mix (cDNA, 2X Probes master mix, polymerase 
chain reaction (PCR)-grade water) was prepared for each 
cDNA sample to which either query or normalizing 
TaqMan primers/probe was subsequently added. This pro-
cedure allows the query and normalizing primers/probe to 
interrogate the same cDNA master mix preparation, 
resulting in more accurate normalization.15 Normalized 
Cp values (critical point; Cpquery—geometrix-mean 
(CpPPIA, Cp18S)) were analyzed. In addition, relative quan-
titative reverse transcription–polymerase chain reaction 
(RT-PCR) (quantitative polymerase chain reaction 
(qPCR)) gene expression for differentiated islet-like pan-
creatic cells were analyzed against human islets served as 
a positive control and acinar and undifferentiated MSCs 
as a negative control.
Nanogland fabrication
For nanogland (NG) fabrication, we used a 3D printer 
(Makerbot 2X; Makerbot Industries New York, USA). 
This 3D printer runs on fused deposition modeling 
(FDM) technique, building parts layer-by-layer from the 
bottom-up by heating and extruding thermoplastic fila-
ment. A solid modeling software (SolidWorks®, Dassault 
Systèmes SolidWorks Corp.) was used to create a 3D 
dataset for the fabrication process. Biocompatible PLA 
(Foster Corporation, CT, USA) was used to fabricate the 
NGs (Figure 5).
The NG consists of a cell reservoir (250µL) and has a 
discoidal shape with a diameter of 13 mm and a thickness 
of 4.5 mm. The cell reservoir consists of an array of micro-
chambers (200 µm × 200 µm) to house each pancreatic islet 
or ILIPA individually. The microchambers are connected 
to the outside by an array of square microchannels 
(150 µm × 150 µm cross section and 50 µm length).
NG surface patterning and modification
After fabrication, NG surface modification was performed, 
using various agents as described below to obtain suitable 
external charge and hydrophilicity for supporting cell 
growth and viability. All of the PLA NGs were immersed 
in a 5-M NaOH (Macron Chemicals, PA, USA) solution in 
Millipore water for 4 h under mild agitation, then rinsed, 
and dried at room temperature. A NG custom holder has 
been fabricated for running two 60-s cycles of argon 
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plasma (Ar) or oxygen plasma (O2) etching (30 W, 
150 mTorr) (March plasma etcher, Nordson, OH, USA).
Five NGs were placed in a petri dish filled with a poly-
L-lysine (PLL) solution 0.01%, 150,000–300,000 MW 
(PLL, Sigma Aldrich), incubated for 5 min, and air dried at 
room temperature. The second group of five NGs was 
placed in a petri dish filled with endothelial cell attach-
ment factor (ECAF; Sigma Aldrich, sterile-filtered liquid), 
followed by a 10-min incubation, and dried at room tem-
perature, as per manufacturer’s instructions.
Stability of surface modification in vitro
All surface-modified NG groups were immersed in PBS 
for 40 days under gentle agitation at 37°C. NG surface 
conformation and water contact angle were measured at 
different time points (1, 3, 7, 14, 21, 28, and 40 days), and 
the images were analyzed using ImageJ software.
Cell viability in surface-modified NGs in vitro
For the in vitro cell viability study, flat PLA membranes 
(n = 7) were printed (20 mm diameter, 1 mm thickness); 
treated with NaOH, argon plasma, PLL, and ECAF (n = 6 
per each group); assembled into 6-well polystyrene cell 
culture inserts (Becton Dickinson); and filled with 1.5 × 105 
human umbilical vein endothelial cells (HUVECs) in a vol-
ume of 1 mL of complete endothelial cell basal medium 
(EBM, Lonza, USA). All samples were incubated at 37°C 
and 5% CO2 for 7 days with a change of media at regular 
time intervals (2, 4, and 7 days). To assess viability, cells 
were rinsed with PBS buffer, trypsinized (trypsin/ethylen-
ediaminetetraacetic acid (EDTA) solution), and quantified 
using Trypan blue solution.
Assessment of insulin secretion and content in 
vitro
Standard aliquots of 50 islets equivalent (IEQ) or 100 IEQ of 
ILIPAs were incubated for 60 min with low glucose (60 mg/
dL, basal), followed by 60 min of high glucose (300 mg/dL, 
stimulated).16 Following high-glucose incubation, islets were 
harvested and insulin was extracted in an ethanol–acid solu-
tion (165 mM HCl in 75% ethanol). The islets were then ana-
lyzed for insulin content using a specific enzyme-linked 
immunosorbent assay (ELISA) assay (ALPCO Diagnostics, 
Windham, NH). The low-glucose medium used was stand-
ard alpha MEM supplemented with 5% platelet lysate (PL). 
The high-glucose stimulation medium was high-glucose 
D-MEM (450 mg/dL glucose) supplemented with 5% PL.
ILIPAs insulin secretion in NG
In order to assess the long-term viability of ILIPAs when 
housed in the NG device, we loaded multiple NGs (10 per 
group) with approximately 2000 ILIPA constructs. The 
ILIPAs were loaded in a PL gel into the NG. Briefly, NGs 
were placed in the wells of a sterile 12-well suspension 
type plate (Sarstedt). ILIPAs were centrifuged and medium 
was removed. The ILIPAs were mixed with PL at a con-
centration that would allow for approximately 2000 ILIPAs 
to be loaded in a volume of 200 µL (10,000 ILIPAs/mL). 
Three NG treatment types were tested in this evaluation: 
NGs without surface modification (untreated), NGs’ sur-
face modified with argon plasma, and NGs’ surface modi-
fied with oxygen plasma. Once the PL-ILIPAs were loaded 
into the wells, 50 µL of thrombin (2000 units/mL; King 
Pharma, Bristol, TN) was mixed with the solution. The 
plates were placed in a 37°C, 5% CO2 incubator for 60 min 
to allow complete formation of the gel.
Once gelation was accomplished, the NGs were trans-
ferred into new microplates and 3 mL of alpha MEM with 5% 
PL was added to the wells. The medium was replaced every 
3–4 days for the next month. The NGs were tested weekly for 
insulin release using a perifusion-type evaluation.
On days 7, 14, 21, and 28, the medium was collected 
from the NG wells and saved for insulin analysis. The 
medium was replaced with fresh medium that represented 
the low-glucose portion of the testing (100 mg/dL). The 
plates were incubated for 30-min intervals, and the medium 
was harvested for insulin analysis every 30 min for up to 
6 h. The medium was changed to high-glucose medium at 
90 min and remained so until the final incubation of the day. 
At this time, the medium was replaced with low-glucose 
medium, and the plates were returned to the incubator over-
night. The following morning, medium was collected and 
again replaced with high-glucose medium, with incubation 
extending up to another 3–4 h.
Statistical analysis
Results are expressed as means and standard deviations for 
at least three replicates. One-way nonparametric analysis 
of variance followed by Tukey’s post hoc test was assessed 
to verify statistical significance; p < 0.05 was considered 
statistically significant. Statistical analysis was performed 
using Prism 5 software (GraphPad Software Inc., San 
Diego, CA, USA).
Results
Morphological and phenotypical 
characterization of the cultured MSCs
At the end of the expansion phase, the cells became 
homogenous, spindle shaped, fibroblast-like and arranged 
in monolayers (Figure 1c). Flow-cytometric analysis 
showed that they expressed high percent levels of CD29 
(80.4±17.1), CD44 (47.8±25.8), and CD106 (10±19.5), 
but negligible levels of CD14 (1±1.5), CD34 (2.7±1.7) and 
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CD45 (7.6±6.9). These results indicate that majority of the 
bone marrow-derived cells were MSCs and that the num-
ber of MSC obtained at the end of the expansion phase 
varies from one donor to another.17 During the MSC dif-
ferentiation into ILIPA phase, cells gathered gradually in 
groups with the formation of three-dimensional aggre-
gates. At the end of the differentiation protocol, cells 
formed clusters with spheroidal morphology (Figure 1). 
A difference in the rate of growth or differentiation was 
observed between different donors (data not showed).
At the end of differentiation, immunofluorescent labe-
ling and electron microscopy demonstrated c-peptide posi-
tive staining in the differentiated ILIPAs.
Furthermore, using immunohistochemistry we show 
that differentiated ILIPAs contain α-cells that are posi-
tively stained for glucagon and β-cells positively stained 
for insulin (Figure 2 and Supplementary Figure 1).
Gene expression profile of human pancreatic 
islets and ILIPAs
Human islets (n = 5) and ILIPAs (n = 5) were analyzed 
for gene profile using high-density Affymetrix U133A 
Gene Chips (analyzed by Gene Spring software). Genes 
that met the criteria for statistically significant differen-
tial expression (p ⩽ 0.01) at false discovery rate of 2% 
were identified by Welch’s t-test. This list was further 
refined by omitting those genes whose fold-difference of 
expression was less than two. Using Ingenuity Pathways 
Analysis software, we identified differential gene 
expression profiles in islets that play a role in insulin 
synthesis and secretion as well as glucose metabolism 
(Supplementary Table 1 and Figure 3). While there was 
no difference in the insulin expression between islets 
and ILIPAs, islets had high relative levels of genes that 
promote insulin production and secretion, such genes 
included ABCC8, PDX1, RFX6 PCSK1, SLC2A2, 
FOXA2, and SST.
RT-PCR of differentiated ILIPAs
Islet gene expression profile varies in different donors. To 
determine the variation in gene expression profile of dif-
ferent ILIPA preparations, we examined five differentiated 
ILIPA preparations and compared them to an average of 
five human islet preparations as a positive control and to 
undifferentiated MSCs and acinar cells as a negative con-
trol. We tested for genes that are crucial for insulin secre-
tion and glucose metabolism and results expressed by 
previous gene expression array, such as Insulin, SST, 
ABCC8, SC2A2, PDX1, FOXA2, RFX6, and PSCK1. As 
shown in Figure 4, there is a wide variation between differ-
ent ILIPA preparations, where two out of five have similar 
expression levels as the islets.
NG surface treatment and endothelial cell 
culture
Different surface treatments were tested to augment PLA 
NG hydrophilicity (Table 1; Figure 5). All of the tested 
surface modifications reduce water contact angle on the 
polymer surface in the first week after treatment. The 
effect was higher when the NGs were treated with a com-
bination of Ar plasma and ECAF (p < 0.001), but this group 
Figure 1. Morphological changes of bone marrow–derived cells (MSCs) differentiated into functional islet-like structures (ILIPAs): 
(a) bone marrow cells; (b) purified MSC; (c) undifferentiated MSCs, at the end of the expansion phase; and (d) contrast phase 
microscopy showing aggregation of differentiating MSCs into insulin-producing ILIPA.
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lost the hydrophilic change in almost 1 week, becoming 
comparable to the other treated groups. All the groups 
treated with Ar plasma maintained the surface characteris-
tics, as shown by low contact angle at 1 month from the 
surface treatment (p < 0.01), but only the combination with 
PLL and ECAF maintained the effectiveness at day 40 
(p < 0.05) (Figure 6).
Cell proliferation and viability were tested in surface-
modified NGs using HUVECs. HUVECs were grown on 
NGs treated with PLL and Ar. Plasma treatment showed a 
slower growth compared to all the other surface treatments 
(p < 0.05). All groups cultured in surface-treated NGs 
showed a mean viability higher than 90%, and dimension 
comparable to control, with minor differences between the 
control and untreated NGs (16.81 vs 15.54 µm, p < 0.05). 
All cells cultured inside the NGs grew slower than the con-
trol group cultured in classical polystyrene well (p < 0.001) 
(Figure 7).
Insulin secretion by ILIPAs in NG
A month-long ILIPA culture was conducted in polymeric NGs 
with different surface treatments to understand long-term via-
bility and insulin secretion in response to glucose stimuli.
ILIPAs showed an ability to produce steady levels of insu-
lin throughout the testing process. The insulin accumulated in 
the testing media in a consistent manner showing spikes in 
insulin production and accumulation at time 0 (following 
weekend incubation) as well as following overnight incuba-
tion during the testing. These spikes seem constant during the 
entire duration of study, with a statistically non-significant 
reduction trend during week 4 in all groups. There were no 
differences in both basal insulin secretion and response to 
high glucose in argon- or oxygen-treated NGs. ILIPAs 
showed no significant difference in overall performance over 
the testing period when different types of surface treatments 
Figure 2. Differentiated ILIPAs (b) are similar in size to human islets (a). ILIPA EM photomicrograph (d) stained with gold 
nanoparticles labeled with antibodies to C-peptide (black arrows) at the cisternae of rough endoplasmic reticulum (c) and (d).
Figure 3. Glucose metabolism disorder network generated 
using Ingenuity Pathways Analysis software comparing human 
islets to ILIPAs. Upregulated genes are shown in red and 
downregulated genes in green. Genes that are important to 
glucose metabolism such as ABCC8, RFX6, and SLC2A2 are 
expressed much higher in the islets with fold changes of 79, 
138, and 21, respectively.
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were compared and insulin release tracking was consistent 
for each NG cohort (Figure 8).
When comparing ILIPAs in the NG-PL to free ILIPAs 
tested in the same manner, we see a rapid drop in insulin 
levels for the free ILIPAs compared to those in the NG 
devices, presumably due to retention of insulin within the 
PL gel matrix (Figure 8(a)).
Discussion
Over the last few decades, islet and stem cell transplanta-
tion has been explored as a promising method to achieve 
strict control of blood glucose and as a potential cure for 
diabetes. Two key problems for these cell therapies are the 
lack of adequate islets or islet-like tissue and the need to 
use immunosuppressants. Here, we develop a new, alterna-
tive advanced cell therapy for diabetes based on human 
MSCs. MSCs are multipotent stromal cells with the ability 
to proliferate and differentiate into a variety of cell types 
including insulin-producing cells. Since MSCs comprise 
only 0.001% to 0.01% of bone marrow mononuclear 
cells,17–20 in vitro expansion of these cells is necessary to 
obtain sufficient cell numbers for clinical use. Following 
the expansion phase, cells were driven to differentiate into 
ILIPAs that express pancreatic islet genes and secrete insu-
lin. The premise of stem cell therapy for diabetes is the 
production of autogenous differentiated cells that mimic 
pancreatic islets and β-cells as a source of insulin for blood 
glucose homeostasis.17 Our data show that despite the suc-
cess in creating ILIPAs that are capable of insulin and 
C-peptide production, there was a variation among cul-
tures from different donors in key transcriptional factor 
expression such as PDX1, a factor responsible for the 
development of the pancreas in humans as well as main-
taining insulin gene expression and β-cell survival. Down 
regulation in the expression of PDX1 could lead to β-cell 
failure and subsequently type 2 diabetes.21 RFX6 was 
another transcription factor upregulated in ILIPAs, com-
monly responsible for the regulation of insulin gene 
expression and secretion and is thought to be involved in 
islet cell differentiation.22
ILIPAs expressed SLC2A2, a gene that produces 
GLUT2, the specific glucose transporter in β-cells, respon-
sible for glucose homeostasis by enabling transport across 
cell membranes, tuning insulin secretion,23 PCSK1, pro-
protein convertase subtilisin kexin type 1 (PCSK1), which 
belongs to the subtilisin-like proprotein convertase family 
that process latent precursor proteins, such as proinsulin, 
into their biologically active products, and ABCC8, a gene 
included ATP-binding cassette, sub-family C (CFTR/
MRP), member 8, which functions as a modulator of ATP-
sensitive potassium channels and insulin release.24,25 
Donor variability is a major concern. Our laboratory found 
that not all donor cells differentiate at the expected time 
frame; indeed some took a longer time to reach the desired 
phase. This variability could be due to differences in age 
and gender.26 Therefore, testing ILIPA preparation with 
RT-PCR for key genes required for healthy islet function 
could be essential for possible future clinical studies. 
RNA-sequencing could be a valid method to further char-
acterize ILIPA gene expression and their biological char-
acteristics, which will require larger quantity of cells. For 
future experiments, we plan to expand the production of 
ILIPAs to be able perform several different analyses.
As reported from the outcomes of currently used clini-
cal protocols for islet transplantation, such as the Edmonton 
protocol, intraportal pancreatic injection does not offer an 
ideal physiological environment for pancreatic islet 
engraftments, and their viability is hampered by acute 
hypoxia after transplantation.27 A possible way to over-
come this limitation is to house pancreatic islets and cells 
in a system able to provide mechanical support, immuno-
logical protection, easy passage of nutrients and oxygen to 
meet the high metabolic demand, while keeping the ability 
to rapidly respond to plasma glucose changes in an 
adequately vascularized subcutaneous environment. It is 
possible to fabricate such tridimensional biomimetic 
encapsulation systems using low-cost and customizable 
3D printers able to print medical grade synthetic polymeric 
material as well as biological tissue to better reproduce 
normal physiology. To enhance the long-term efficacy of 
islet transplantation by improving vascularization while 
reducing immunogenicity, a tissue engineering approach 
of 3D culturing insulin-producing cells encapsulated in 
NGs could be implemented by filling a bioreactor’s inte-
rior with a biomimetic extracellular matrix (ECM)-like 
scaffold and seeding with pancreatic β-cells or islets.
Implantable biocapsules have been proposed as a prom-
ising approach for transplanting cells and protecting them 
from immune rejection.28 Ferrari et al. demonstrated that 
silicon based cell biocapsules have the advantage of 
mechanical strength and biochemical inertness.29,30
Table 1. Water contact angle of PLA after different surface treatments.
Day 0 Day 1 Day 10 Day 30 Day 40
Control 74.92 (3.43) 73.25 (2.02) 72.75 (3.88) 72.10 (3.23) 67.61 (3.93)
Ar 39.95 (5.76) 40.05 (1.54) 40.25 (4.11) 51.32 (1.35) 69.29 (1.14)
Ar + PLL 53.41 (2.35) 52.65 (5.51) 45.10 (3.57) 49.22 (2.46) 57.54 (3.63)
Ar + ECAF 8.27 (6.72) 20.00 (5.35) 41.20 (6.23) 51.41 (5.32) 58.12 (5.56)
PLA: polylactic acid; Ar: argon plasma; PLL: poly-L-lysine; ECAF: endothelial cell attachment factor.
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Figure 4. Real-time PCR of islet’s key transcription factors expression of acinar cells, undifferentiated MSC, and differentiated 
ILIPAs from five different donors, normalized to five different isolated human islets. The results are expressed as the fold change 
difference of islets to ILIPAs.
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Silicon membranes were microfabricated with photo-
lithographic techniques allowing for fine control over pore 
size and distribution in the 20–100 nm range.31
Our group is developing a NG system composed of bio-
compatible silica or polymeric encapsulation with insulin-
producing cell clusters contained in a 3D biological matrix 
providing the ability to replace physiological function of 
native islets for diabetes treatment.
In previous work, we demonstrated that a silicon 
microfabricated device, composed by channels ranging 
from 3.6 nm to 60 µm filled with pancreatic islets, showed 
good glucose response and insulin release in vitro and in 
vivo.29 This “silicon pancreas” provided immunological 
protection and mechanical support for islet growth, but it 
showed limited angiogenic potential and metabolic diffu-
sion when implanted subcutaneously in mice.
To overcome these limits and achieve customization 
and scalability, we developed a new 3D printed NG using 
biocompatible functionalized polymers, fillable with 
ECM-like PL gel matrix to better nurture the pancreatic 
islets or other insulin secreting cells, such as ILIPAs, 
derived by MSCs or other sources.32
Our NGs offer easy evaluation for the role of angiogen-
esis and vascularization on insulin production, glucose 
stimulation, and cell viability and provide co-culturing 
options for pancreatic cells with endothelial cells or other 
vascular progenitor cells.
Furthermore, to address one-by-one all of the pitfalls of 
commonly used pancreatic cell bioreactors and macroencap-
sulation systems, it is possible to functionalize the polymeric 
scaffold, to induce local angiogenesis or endothelial migra-
tion, improve islets’ metabolic function, and reduce the risk 
of immunological rejection. Indeed, surface characteristics 
greatly influence attachment and growth of cells on biomate-
rials. Biocompatible polymers like PLA have been widely 
used as scaffold materials for tissue engineering and implant-
able devices, but the lack of cell recognition sites, hydropho-
bicity, and low surface energy lead to bad cell affinity for 
these polymers, which limit their usage. Plasma surface 
treatment, followed by surface functionalization with cati-
onic groups, has shown to greatly enhance biomimetic prop-
erties of PLA and the consequent affinity for the cells.33 
Additionally, it has been shown that gas-plasma-treated PLA 
scaffolds have the potential to serve as angiogenic scaffolds. 
Prior work with endothelial cells on oxygen plasma treated 
PLA scaffolds has shown increased cell proliferation over 
4–6 days and increased angiogenesis in vivo at 12 days.34 
This characteristic could be very useful for potential clinical 
application, permitting a better vascularization of PLA 
implanted devices used as cell reservoirs.
Xia et al. showed rapid endothelialization of plasma 
treated PLA with functionalized –COOH groups to link 
gelatin or chitosan, while Zhu et al. showed similar results 
through aminolyzed PLA.35,36 A possible advantage of 
polymeric PLA implants is the local lactate release after 
degradation, which seems to improve angiogenesis and 
cutaneous wound healing in different mouse strains.37
To house ILIPAs and support their graft while promot-
ing rapid vascularization, the NGs were fabricated with 
Figure 5. (a) An open section of a 3D printed PLA nanogland showing cell chambers and microchannels; (b) and (c) SEM images of 
the array of microchambers.
Figure 6. Comparison of hydrophilicity achieved by various 
surface modification techniques, as measured by water contact 
angle on day 1 (a = control, b = PLL, c = ECAF) and their stability 
over 40 days.
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microchambers connected to the outside by an array of 
square microchannels with a 150 µm × 150 µm cross sec-
tion, 50 µm in length. Previous works showed that for a 
successful glucose response, it is fundamental to recreate a 
physiological-like environment keeping cell aggregates in 
close proximity, but separate from each other to stimulate 
ingrowth of vessels under hypoxic stimuli.38,39 With the 
microchamber structure, the NG houses one or few ILIPAs 
or islets inside each chamber avoiding clustering.
Nevertheless, further studies are needed to prove the 
effectiveness of this geometry, considering that endothelial 
cells are highly influenced in their behavior and growth 
properties by the geometry of the substrate.40
Similarly, the rigidity of the substrate has a profound 
influence on in vivo function. PLA scaffold rigidity is sev-
eral orders of magnitude higher than the one present in tis-
sue (>103 vs 1–100 kPa). Although increasing evidence 
indicates that cell function maybe dramatically affected by 
non-physiological rigidity,41 HUVECs and ILIPA viability 
and morphology were not affected by NGs in vitro. A pos-
sible alternative for helping the vascularization process, 
reducing the rigidity, could be to use more flexible and 
biocompatible polymers like polycaprolactone (PCL) or 
print vessel-like structures in hydrogel materials.42,43
A major challenge in transplantation is the induction of 
donor specific tolerance. Recently the Food and Drug 
Administration (FDA) approved a CTLA-4Ig fusion pro-
tein that blocks the co-stimulatory receptor CD28 and B7 
interactions, critical to T cell activation for clinical use in 
kidney transplantation.44 A localized delivery of immu-
nomodulator drugs in the vicinity of transplanted tissue, 
which will protect the transplant from immune rejection 
and at the same time eliminate the adverse effects associ-
ated with systemic immunosuppression, is the ideal choice 
Figure 7. Effect of different polylactic acid surface modification techniques on (a) HUVEC viability, (b) growth, and (c) dimension.
*p < 0.05; **p < 0.001.
Figure 8. Effect of nanogland and surface modifications on ILIPAs’ insulin secretions per ILIPA after glucose stimulation during  
(a) the first week of culturing and (b) over a 4-week experiment. Overnight peaks are marked by red arrows.
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in islet/beta cell transplantation. Based on our group’s 
extensive expertise with implantable drug delivery sys-
tems with microfabricated nanochannels, which have 
shown to achieve constant and sustained delivery of vari-
ous therapeutics including testosterone, leuprolide, inter-
feron, lysozyme, genotropin, and octreotide in several 
animal models for periods ranging from 1–6 months,45–49 it 
is possible to incorporate a local sustained delivery of 
immunomodulators in the NG.
ILIPAs, either free or in NGs, did not show a measura-
ble acute response to high glucose as a secretogogue, likely 
due to the lack of insulin storage granules in the ILIPA 
construct. However, all groups demonstrated very consist-
ent low-level insulin production throughout the testing 
period and as such, may prove clinically useful as a 
replacement source of basal levels of insulin. All tissues 
tested resulted in a basal insulin level of 0.012–0.072 µU 
insulin per ILIPA (data not shown). An interesting obser-
vation was that free ILIPAs showed a quicker reduction in 
insulin release than those housed in NGs, presumably due 
to insulin accumulation in the PL gel matrix in the latter. 
Also, ILIPA overnight incubation in NGs produced higher 
insulin spikes. In translating these results to clinically rel-
evant models, it would be interesting to observe vasculari-
zation, innervation, and immunological response to the 
encapsulated ILIPAs in murine and other animal models of 
diabetes, and their long-term effectiveness in maintaining 
euglycemia, reducing disease progression, and preventing 
associated complications.
Conclusion
This work demonstrates the generation of insulin-produc-
ing cells from human BM-MSCs capable of prolonged and 
sustained in vitro insulin production. The ILIPAs can be 
generated autologously, and while they do not provide a 
prompt insulin response to secretogogues, we demonstrate 
prolonged and sustained in vitro production of insulin that 
could provide a consistent basal level of insulin in a trans-
plant scenario. Furthermore, we designed and developed a 
biomimetic NG encapsulation system suitable for long-
term cell replacement therapy with islets, ILIPAs, or other 
insulin-producing cells. This construct could be useful to 
test the effect of different materials, surface modifications, 
and matrices on pancreatic cells properties, such as cell 
viability, glucose response, and insulin secretion under dif-
ferent stress conditions, localized angiogenesis, and 
immune-tolerance induction. Our NG could potentially 
overcome many of the hurdles of current islet transplanta-
tion strategies. Moreover, by improving the 3D printing set 
up and pairing with new cell electrospinning techniques, it 
is possible to print other 3D organotypic scaffolds to test 
the growth of different cell lines suitable for other clinical 
applications.50,51 Further advances in the stem cell field 
and encapsulation technology may result in the ultimate 
goal of developing a true replacement of pancreatic endo-
crine function through a bioartificial pancreas.
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